Literature DB >> 22920545

Is a visible (hypoechoic) lesion at biopsy an independent predictor of prostate cancer outcome?

Valeria Cristina Nakano Junqueira1, Orlando Zogbi, Adauto Cologna, Rodolfo Borges Dos Reis, Silvio Tucci, Leonardo Oliveira Reis, Antonio Carlos Westphalen, Valdair Francisco Muglia.   

Abstract

The aim of this study was to evaluate the prognostic implications of the sonographic appearance of prostate cancers. All patients with biopsy-proven prostate cancer between January 2003 and July 2004 (and at least 5 years of follow-up) were selected retrospectively. After exclusions, 101 patients constituted our study population and were divided into isoechoic (or nonvisible) and hypoechoic (or visible) lesion. The clinical outcomes of these two groups were compared. The outcomes for the two groups were significantly different (p < 0.01). For nonvisible lesions, 37 of the 41 patients (90.2%) had no disease relapse and 2 (4.9%) had biochemical failure. For the visible lesions, 37 of the 60 (61.6%) patients were free of recurrence, 7 (11.7%) had systemic metastases and 10 (16.7%) died of complications related to prostate cancer. Our data show that patients with nonvisible prostate cancer had significantly better outcomes than patients with visible lesions during a five-year period of evaluation.
Copyright © 2012 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22920545     DOI: 10.1016/j.ultrasmedbio.2012.06.006

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  6 in total

1.  Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study.

Authors:  Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  World J Urol       Date:  2018-03-05       Impact factor: 4.226

2.  TRUS-MR Fusion Biopsy of the Prostate: Radiological and Histological Correlation.

Authors:  Michel Lavaerts; Liesbeth De Wever; Els Vanhoutte; Frederik De Keyzer; Raymond Oyen
Journal:  J Belg Soc Radiol       Date:  2016-11-24       Impact factor: 1.894

3.  A Nomogram Based on a Multiparametric Ultrasound Radiomics Model for Discrimination Between Malignant and Benign Prostate Lesions.

Authors:  Lei Liang; Xin Zhi; Ya Sun; Huarong Li; Jiajun Wang; Jingxu Xu; Jun Guo
Journal:  Front Oncol       Date:  2021-03-02       Impact factor: 6.244

4.  Usefulness of grayscale values measuring hypoechoic lesions for predicting prostate cancer: An experimental pilot study.

Authors:  Jeong Woo Yoo; Kwang Suk Lee
Journal:  Prostate Int       Date:  2021-12-03

5.  Impact of benign prostatic hyperplasia pharmacological treatment on transrectal prostate biopsy adverse effects.

Authors:  Marina Zamuner; Ciro Eduardo Falcone; Arnaldo Amstalden Neto; Tomás Bernardo Costa Moretti; Luis Alberto Magna; Fernandes Denardi; Leonardo Oliveira Reis
Journal:  Adv Urol       Date:  2014-04-28

6.  Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤10 ng/mL?

Authors:  Jee Soo Park; Kyo Chul Koo; Byung Ha Chung; Kwang Suk Lee
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.